TY - JOUR
T1 - Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice
AU - Kurhe, Yeshwant Vijay
AU - Radhakrishnan, Mahesh
AU - Thangaraj, Devadoss
AU - Gupta, Deepali
PY - 2014/1
Y1 - 2014/1
N2 - Objective: To investigate the anti-anxiety activity of "6k", a novel 5-hydroxytryptamine type 3 (5-HT3 ) receptor antagonist in in mice. Materials and Methods: Anti-anxiety activity of "6k" (1,2, and 4 mg/kg, intraperitoneally (i.p.)) was evaluated in mice by behavioral tests such as elevated plus maze (EPM), open field test (OFT), light-dark box (L&D), and hole board test (HBT). Diazepam (2 mg/kg, i.p.) served as reference standard. Results: "6k"significantly (P < 0.05) increased the time and entries in open arm in EPM as compared to vehicle control group. Further, "6k"significantly (P < 0.05) increased the central and peripheral ambulation along with rearings and time in central area; whereas, reduced the fecal pellets in OFT as compared to vehicle control group. There was significant (P < 0.05) reduction in the latency to enter dark chamber; whereas, increased number of crossings and time in light chamber in L&D aversion test by treatment with "6k" as compared to vehicle control group. In HBT, "6k" significantly (P < 0.05) increased the number of head dipping and squares crossed; whereas, reduced the latency for first head dip and number of fecal pellets as compared to vehicle control group. Conclusion: A novel 5-HT 3 receptor antagonist has anti-anxiety action.
AB - Objective: To investigate the anti-anxiety activity of "6k", a novel 5-hydroxytryptamine type 3 (5-HT3 ) receptor antagonist in in mice. Materials and Methods: Anti-anxiety activity of "6k" (1,2, and 4 mg/kg, intraperitoneally (i.p.)) was evaluated in mice by behavioral tests such as elevated plus maze (EPM), open field test (OFT), light-dark box (L&D), and hole board test (HBT). Diazepam (2 mg/kg, i.p.) served as reference standard. Results: "6k"significantly (P < 0.05) increased the time and entries in open arm in EPM as compared to vehicle control group. Further, "6k"significantly (P < 0.05) increased the central and peripheral ambulation along with rearings and time in central area; whereas, reduced the fecal pellets in OFT as compared to vehicle control group. There was significant (P < 0.05) reduction in the latency to enter dark chamber; whereas, increased number of crossings and time in light chamber in L&D aversion test by treatment with "6k" as compared to vehicle control group. In HBT, "6k" significantly (P < 0.05) increased the number of head dipping and squares crossed; whereas, reduced the latency for first head dip and number of fecal pellets as compared to vehicle control group. Conclusion: A novel 5-HT 3 receptor antagonist has anti-anxiety action.
KW - 5-HT antagonist
KW - Anxiety
KW - Elevated plus maze
KW - Hole board test
KW - Open field test
UR - http://www.scopus.com/inward/record.url?scp=84893208187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893208187&partnerID=8YFLogxK
U2 - 10.4103/0253-7613.125186
DO - 10.4103/0253-7613.125186
M3 - Article
C2 - 24550593
AN - SCOPUS:84893208187
SN - 0253-7613
VL - 46
SP - 100
EP - 104
JO - Indian Journal of Pharmacology
JF - Indian Journal of Pharmacology
IS - 1
ER -